London Healthcare Week: Oculis is aiming to redefine ophthalmology through methods like an eye drop technology that can reach the back of the eye and precision medicine like patient selection

blonca9
Nov 19, 2024
1 min read

CEO Riad Sherif introduces us to the company's programs in areas such a diabetic macular edema and dry eye. A phase 2 study in acute optic neuritis will read out within weeks.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

London Healthcare Week: Oculis is aiming to redefine ophthalmology through methods like an eye drop technology that can reach the back of the eye and precision medicine like patient selection

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight